Endocrine & Metabolic Disease Models

In the field of metabolic diseases, we are proud of our portfolio of stable and effective animal models, especially those for Non-alcoholic Fatty Liver Disease (NAFLD). Though popular recently, they still lack effective drug treatment.

Download

Diseases	Models	Animals
Obesity and diabetes	Streptozotocin-induced	Rats/mice
	Spontaneous	Mice (db/db, ob/ob)
	Spontaneous	ZDF rats
	High-fat and high-sugar diet-induced	Mice
Hyperuricemia	Potassium oxonate-induced	Rats/mice
	UA-induced	Mice
	Hypoxanthine-induced	Mice
	Adenine- and ethambutol-induced	Rats
Liver fibrosis	Bile duct ligation	Rats
	TAA-induced	Rats
	Composite factor method-induced	Rats
	ConA-induced	Mice
	Porcine serum-induced	Rats
Lipid abnormality	High fat/cholesterol/fructose diet-induced	Hamster
Lipid abnormality	Hereditary atherosclerosis (APOE mice + high-fat diet)	APOE mice
Non-alcoholic fatty liver (NAFLD, NAFL, NASH)	Hereditary atherosclerosis (APOE mice)	APOE mice
	Non-alcoholic fatty liver	Rats
	High-fat diet (HFD)	Rats/mice, hamsters
	Methionine- and choline-deficient diet (MCD)	Mice
	Composite factor-induced	Rats
Thrombus	Arteriovenous bypass thrombosis	Rats/mice
	Carrageenan-induced tail vein thrombosis	Mice
	Deep vein thrombosis	Rats
	Carotid artery thrombosis	Rats/mice

Cardiovascular and cerebrovascular diseases generally refer to ischemic or hemorrhagic diseases of the heart, brain and systemic tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, and hypertension. Medicilon has established rat and mouse MCAO model evaluation system with stable lesions, high success rate, high survival rate and reliable and effective evaluation of dose-effect/time-effect relationship. We can provide efficacy evaluation of transient cerebral ischemia and permanent cerebral ischemia and complete the investigation of various pharmacodynamic core indicators according to STAIR technical guidelines. The model rodents could be customized with special diseases and complete activity evaluations according to customer requirements.

Disease Name	ICD 10	Model
Intracerebral hemorrhage	I60-I62	Intracranial autologous blood injection, subarachnoid hemorrhage
Cerebral infarction	I63	Ischemic stroke model
Stroke	I64
Cerebral Embolism	I65
Cerebral Embolism	I66
Other	I67-I69	Other

FAQ

What is the Difference Between NAFL and NASH?

NAFL:
It is completely reversible and can be completely reversed through a healthy lifestyle such as diet and exercise controlling diet, exercise and other healthy lifestyles. Drug therapy is mainly to improve lipid metabolism.
NASH:
It is a progressive form of nonalcoholic fatty liver disease, a metabolically stressful metabolic stress liver injury closely associated with insulin resistance and genetic predisposition, can progress to cirrhosis and hepatocellular carcinoma. It was also significantly associated with an increased risk of cardiovascular disease.
The etiology of NASH is complex, and the exact pathogenesis is unknown. There is no specific treatment or drug therapy for Nash.
NASH treatment drugs with different targets have become one of the current research and development hotspots, which target the different pathogenesis of NASH, such as liver metabolism, inflammation, oxidative stress, fibrosis, etc.

Relevant laboratories

Relevant articles

Digestive System Disease Models Endocrine & Metabolic Disease Models Inflammatory & Immune Diseases Models Neural System Disease Models Other Disease Models